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Abstract
Background: Absent T-cell immunity resulting in life-threatening infections provides a clear 
rationale for hematopoetic stem cell transplantation (HSCT) in patients with severe combined 
immunodeficiency (SCID). Combined immunodeficiencies (CIDs) and “atypical” SCID show 
reduced, not absent T-cell immunity. If associated with infections or autoimmunity, they represent 
profound combined immunodeficiency (P-CID), for which outcome data are insufficient for 
unambiguous early transplant decisions.
Objectives: We sought to compare natural histories of severity-matched patients with/without 
subsequent transplantation and to determine whether immunologic and/or clinical parameters may 
be predictive for outcome.
Methods: In this prospective and retrospective observational study, we recruited nontransplanted 
patients with P-CID aged 1 to 16 years to compare natural histories of severity-matched patients 
with/without subsequent transplantation and to determine whether immunologic and/or clinical 
parameters may be predictive for outcome.
Results: A total of 51 patients were recruited (median age, 9.6 years). Thirteen of 51 had a 
genetic diagnosis of “atypical” SCID and 14 of 51 of CID. About half of the patients had less than 
10% naive T cells, reduced/absent T-cell proliferation, and at least 1 significant clinical event/year, 
demonstrating their profound immunodeficiency. Nineteen patients (37%) underwent 
transplantation within 1 year of enrolment, and 5 of 51 patients died. Analysis of the HSCT 
decisions revealed the anticipated heterogeneity, favoring an ongoing prospective matched-pair 
analysis of patients with similar disease severity with or without transplantation. Importantly, so 
far neither the genetic diagnosis nor basic measurements of T-cell immunity were good predictors 
of disease evolution.
Conclusions: The P-CID study for the first time characterizes a group of patients with 
nontypical SCID T-cell deficiencies from a therapeutic perspective. Because genetic and basic T-
cell parameters provide limited guidance, prospective data from this study will be a helpful 
resource for guiding the difficult HSCT decisions in patients with P-CID.
Keywords
T-cell deficiency; combined immunodeficiency; hematopoietic stem cell transplantation; natural 
history
Human genetic disorders leading to deficiencies in T-cell number and/or function are a 
heterogeneous group of inherited diseases. They can range from absent T-cell immunity with 
early onset of severe clinical manifestations to significant residual T-cell immunity with late 
onset of milder clinical manifestations. The characteristic clinical feature of complete T-cell 
deficiencies is infection susceptibility, while incomplete T-cell deficiencies in addition 
present with manifestations of impaired immune regulation and malignancy.1–4 The key 
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treatment to restore T-cell immunocompetence is hematopoetic stem cell transplantation 
(HSCT) and in some cases gene therapy or enzyme replacement therapy. There is little 
debate that this intensive therapy is required to prevent lethal complications in patients with 
absent T-cell immunity. However, the threshold of T-cell immunity required to prevent 
severe clinical complications is unknown. In patients with low to intermediate T-cell 
function, it is therefore frequently difficult to make a prognosis and to balance this prognosis 
against the risks of HSCT.
Currently, there is no accepted classification of T-cell deficiencies established from this 
therapeutic perspective (for present classifications of T-cell disorders, see Table E1 in this 
article’s Online Repository at www.jacionline.org). Patients with very low T-cell numbers 
are usually classified as severe combined immunodeficiency (SCID). Although these 
patients have a clear HSCT indication, this classification does not consider that there are also 
patients with normal T-cell numbers, but severely impaired T-cell function with the same 
risk for early severe complications and the same clear HSCT indication (eg, ORAI calcium 
release-activated calcium modulator 1 [ORAI1], caspase recruitment domain family, 
member 11, or IkBkB deficiency or patients with the IL-2 receptor gamma chain 
[IL2RG]R222C mutation). At the other end of the spectrum, common variable 
immunodeficiency (CVID), although predominantly an antibody deficiency,5 can be 
associated with significantly impaired T-cell immunity and manifestations related to this.6,7 
Current definitions also do not consider a threshold of T-cell immunity below which the 
diagnosis of CVID is inappropriate and early HSCT is a necessary consideration. 
Preliminary criteria for a threshold of T-cell immunity separating CVID from more profound 
T-cell deficiencies, which we derived by expert consensus in the European Society for 
Immunodeficiencies (ESID) Registry Working Group, remain to be prospectively validated.8
In this study, we focus on patients with disorders of T-cell immunity that can neither be 
classified as SCID nor as CVID, but rather as combined immunodeficiencies (CIDs). Our 
present article considers the following categories of CID, including “atypical SCID,” taking 
into consideration the previous work of Roifman et al3 and Felgentreff et al14: (1) “bona 
fide” CID, diseases in which mutations in affected genes cause T-cell deficiencies and the 
clinical problem is mainly restricted to the immune system (eg, lymphocyte-specific protein 
tyrosine kinase, IL2-inducible T-cell kinase [ITK], zeta-chain (TCR)-associated protein 
kinase 70kDa [ZAP70], macrophage stimulating 1, Coronin 1A, dedicator of cytokinesis 8, 
dedicator of cytokinesis 2, and MHC class I and II deficiencies).9–13 A subgroup are 
syndromic CID, diseases in which mutations cause additional clinical problems (eg, 
cartilage hair hypoplasia, severe cases of 22q11 deletion syndrome, Cernunnos, and STIM1 
or purine nucleoside phosphorylase deficiencies); (2) atypical SCID,14 in which patients 
survive infancy despite T-cell deficiencies caused by hypomorphic mutations in SCID-
associated genes (eg, recombination-activating genes [RAG] 1/2, DNA cross-link repair 1C 
[DCLRE1CI], IL2RG, ORAI1, or inhibitor of kappa light polypeptide gene enhancer in B-
cells, kinase beta [IKBKB]); and (3) CID of unknown cause, in which T-cell deficiency can 
be documented, but no disease-causing mutation is detected. We label patients from 1 of 
these 3 groups of patients with CID as profound combined immunodeficiency (P-CID) if 
their T-cell deficiency is associated with at least 1 severe infection or manifestation of 
impaired immune regulation.
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The motivation for the P-CID study is the recurrent difficult question, if and at what time 
point HSCT should be performed. The study therefore targets patients in whom impaired T-
cell immunity leads to significant complications, but is not severe enough for an 
unambiguous early transplant decision. We prospectively collect data on mortality, 
morbidity, quality of life (QOL), and treatment decisions on parameters of T-cell immunity 
and on results of genetic studies in (initially) nontransplanted children with CID. The goal of 
the study was to analyze these data for predictors of outcome to provide guidance on 
whether and when patients with CID should undergo transplantation. Here, we report interim 
analysis of the first 51 patients recruited, to evaluate the feasibility of the study concept and 
raise awareness for our project.
METHODS
Study design and objectives
The P-CID study is a prospective international multicenter observational cohort study. The 
study protocol has been published.15 The primary objective was to compare data on the 
natural history of age and severity-matched patients with P-CID with or without 
transplantation after study inclusion. Secondary objectives were to determine whether and 
which immunologic parameters and clinical events (eg, infections, immune dysregulation, 
and chronic lung disease) are predictive for outcome, assessed as mortality, morbidity, and 
QOL. The main hypothesis is that patients with P-CID undergoing early HSCT have a better 
5-year survival than patients with similar disease severity who undergo late HSCT or no 
HSCT. Fig 1, A, illustrates the study design. Patients are evaluated and treated according to 
local protocols, including the HSCT decision. Baseline and follow-up documentation of 
genetic, immunologic, and clinical parameters including infections and manifestations of 
immune dysregulation, the transplant decision, severe transplant-related events, and QOL is 
provided on standardized case report forms provided through the study Web site (www.pcid-
study.org). At least 6 yearly study visits are scheduled.
Inclusion and exclusion criteria
Inclusion criteria are shown in Fig 1, B. We recruit nontransplanted patients with impaired 
T-cell immunity and at least 1 associated clinical manifestation (infection, immune 
dysregulation, or malignancy) who are 1 year or older and 16 years or younger at inclusion. 
The definition of impaired T-cell immunity was derived from a previous retrospective 
analysis of 73 patients with atypical SCID, where a combination of at least 2 of 4 abnormal 
T-cell criteria (CD4 or CD8 T-cell counts, percentage of naive CD4 T cells, T-cell 
proliferation, and percentage of γ/δ T cells) best characterized the cohort.14 Because of lack 
of standardized protocols for proliferation to anti-CD3 stimulation, we initially only 
considered results of PHA stimulation for the assessment of T-cell proliferation. After the 
first 20 patients, we realized that good coverage of our target population required the 
inclusion of anti-CD3 proliferation data. An amendment of the study protocol was issued 
and retrospective data were obtained where possible. However, for the present interim 
analysis, these data are still incomplete and only PHA responses were evaluated. We exclude 
patients with typical SCID16 phenotype, defined by (1) presentation with a SCID-defining 
infection (eg, pneumocystis jirovecii pneumonia, persistent cytomegalovirus, or generalized 
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BCG infection) or Omenn syndrome in the first year of life AND (2) evidence of impaired 
T-cell immunity (CD3+ T-cell counts of <300/μL OR absent PHA or anti-CD3 response) 
AND (3) absence of evidence for a secondary immunodeficiency. The requirement for 
significantly impaired T-cell immunity delineates patients with P-CID from patients with 
mild CID and CVID.8 We exclude patients with Wiskott-Aldrich syndrome, CD40 ligand 
deficiency, or ataxia telangiectasia because larger cohorts have been published, offering the 
potential to address the P-CID study question in a disease-specific way.17,18
Patient recruitment
The first 51 patients were recruited at 15 study centers between November 2011 and March 
2014. After informed consent had been obtained from the parents/legal guardians, eligibility 
was verified by the principal investigator on the basis of assessment of inclusion and 
exclusion criteria. The study was approved by local ethics committees (lead institutional 
review board approval by University of Freiburg, institutional review board no. 230/11) and 
registered in the World Health Organization study registry (www.drks.de/DRKS00000497).
Morbidity measure and disease categorization
To provide a quantification of clinical problems that have developed because of the 
immunodeficiency over time until study entry, a morbidity measure was calculated on the 
basis of the following 5 items: invasive bacterial infection (including pneumonia), viral or 
opportunistic infection, autoimmune cytopenia, other immune dysregulation, and chronic 
lung disease. For each patient, the number of clinical events related to this morbidity item 
(from birth up to study inclusion) was counted and divided by the patient’s age to correct for 
the time of exposure. The resulting 5 scores were added and used as a measure of morbidity. 
One limitation of the morbidity measure is the failure to differentially weigh acute versus 
chronic events. Each episode of an autoimmune disease requiring treatment and each acute 
infection requiring admission to hospital counted as a single severe event. Persistent 
infections (eg, EBV, HPV, or molluscum) or persistent immune dysregulation (eg, 
thyroiditis, chronic inflammatory bowel disease, or splenomegaly) were also counted as 
single events. We have used the term “morbidity measure” instead of “morbidity score” to 
reflect that it is a rough, preliminary tool requiring future validation. It is a goal of this study 
to identify the best predictors for a severe outcome and this analysis will allow adapting the 
morbidity measure to a proper risk score, which will then need prospective validation in an 
independent cohort. Because of this limitation, we also categorized the disease at study entry 
as either “severe” or “mild” as judged by the treating physician. This assessment represents 
an overall evaluation of the clinical status at study inclusion. Patients considered for HSCT 
because of overall disease severity or patients considered too sick for HSCTwere rated as 
“severe.” Patients not considered for HSCTor considered for transplantion for “prophylactic” 
reasons only were rated as “mild.”
Statistics
We used Kaplan-Meier plots to illustrate time-to-event data. We purposely elected not to 
provide any P values in this article because this is just an initial analysis. All statistical 
analyses were done using “R” software for Windows, version 3.2.2. (https://www.r-
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project.org/). Further information on the study protocol is available in this article’s Online 
Repository at www.jacionline.org.
RESULTS
Age distribution and genetic characteristics of the first 51 patients
Between November 2011 and March 2014, 51 patients (29 males, 22 females) were 
recruited by 15 centers. A molecular diagnosis was established in 27 of 51 patients (Fig 2, 
A). Thirteen of these had atypical SCID (as defined in the Introduction). Their median age at 
clinical diagnosis was 2.7 years (Fig 2, B). Genetic diagnoses included 7 patients with 
RAG1 or RAG2 mutations, 2 with IL2RG mutations, and 1 each with adenosine deaminase, 
Janus kinase 3, DCLRE1CI, and LIG4 mutations. Fourteen had “bona fide” CID (as defined 
in the Introduction) with mutations in coronin-1A, dedicator of cytokinesis 8 (2), ITK, 
tripeptidyl-peptidase II, and ZAP70 (2), purine nucleoside phosphorylase, PIK3CD, 
caspase-10, and RNA component of mitochondrial RNA processing endoribonuclease, while 
3 had nibrin mutations. Their median age at clinical diagnosis was 2.6 years. In the 24 
patients without genetic diagnosis, the median age at diagnosis was 4.9 years (Fig 2, B). The 
median age at study entry was 9.6 years (1.2–16 years) without apparent differences 
between the 3 groups (Fig 2, C).
Analysis of CID-related illnesses
Seventy-six percent of patients had their first clinical manifestation before the age of 5 years 
in all 3 patients groups (Fig 3, A). Among the events observed during the first year after 
initial presentation, 37% were infections, mostly invasive bacterial infections (including 
pneumonia; 17%) and severe acute viral infections (12%). Notably, 51% of events were 
related to immune dysregulation, most frequently severe eczema (17%), autoimmune disease 
(12%), and autoimmune cytopenia (11%) followed by lymphoproliferation (7%) and 
inflammatory bowel disease (4%) (Fig 3, B). Other organ manifestations including chronic 
lung and liver disease were diagnosed in the first year of illness in 7% of patients each. 
Among all events that had occurred until study inclusion in all patients, 51% were 
manifestations of immune dysregulation, a third of which were episodes of autoimmune 
cytopenia, while the other half were infections or chronic lung disease (Fig 3, C). To further 
characterize the spectrum of clinical manifestations until study entry, we grouped the 
patients according to the percentage of infectious versus immune dysregulation events in 
their individual history. Remarkably, although most patients had both infections and immune 
dysregulation, patients with a predominant immune dysregulation phenotype were more 
frequent than those with a predominant infection phenotype (Fig 3, D). This distribution was 
not different in patients judged to have a mild versus severe clinical phenotype.
Patient morbidity, treatment, and QOL
Most patients had 0.5 to 1 clinical event per year, whereas several had 2 to 4 events with no 
relevant differences between the patient groups (Fig 4, A). QOL was reduced compared with 
a healthy reference population (Fig 4, B). Overall disease severity (mild vs severe) as judged 
by the treating physician delineated 2 groups with different rates of accumulation of severe 
events (see Fig E1, A, in this article’s Online Repository at www.jacionline.org). The 
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physician judgment correlated well with the morbidity measure and QOL (Fig E1, B and C). 
The severity of the disease course in this P-CID cohort was also illustrated by the treatment 
history. Twenty patients (39%) had received steroids, 10 patients immunosuppressive drugs, 
and 9 patients rituximab, while 2 patients were splenectomized. Forty patients (78%) 
received immunoglobulins (the 11 other patients either had normal vaccine responses or 
were just recently diagnosed and therefore not yet on immunoglobulin substitution) and 48 
(94%) received prophylactic antimicrobials, mostly cotrimoxazole. One patient with later-
diagnosed RAG1 deficiency received IgG replacement after a bacterial pneumonia at age 6 
months, but none of the other patients had received prophylactic treatment in infancy.
Immunologic parameters at study entry
T-cell counts were variable without significant differences between the patient groups (Fig 5, 
A). Twenty-four patients (47%) had CD4 counts below 300/μL and 30 (59%) had CD8 T-
cell counts below 300/μL. The median percentage of naive CD4+ T cells was around 10% in 
all patient groups (Fig 5, B), and 34 patients (74%) had below 20% naive T cells. Fourteen 
of 36 patients (39%) had above 20% γ/δ T cells (Fig 5, C), with a similar distribution in all 
groups. Surprisingly, we did not observe relevant differences in any of these T-cell 
parameters between patients categorized as mild or as severe by the treating physician (Fig 
5, A–C). PHA responses were absent or low in 31 (61%) (Fig 5, D).
Analysis of HSCT decisions
Sixteen of 51 patients (31%) underwent transplantation within the first year after inclusion, 
and 3 additional patients underwent transplantation within current follow-up (Fig 6). The 
percentage of patients with atypical SCID (as defined in the Introduction) who underwent 
transplantation within the first year was twice as high as that of patients without molecular 
diagnosis. Interestingly, of 22 patients with severe disease as judged by the treating 
physician, only 13 underwent transplantation. Reasons for not transplanting included lack of 
donor (3), disease too severe (3), family denial (4), and death (2). However, of 29 patients 
with mild disease, 6 underwent transplantation for “prophylactic reasons,” that is, family 
history or because the genetic diagnosis (DCLEREC1, LIGIV, IL2RG, nibrin) was 
considered an HSCT indication. So far, 5 patients died, all from infections: 2 after HSCT 
(RAG1, ZAP70) and 3 without HSCT (ITK, RAG1, RAG2).
Feasibility assessment of a matched-pair analysis
To estimate how informative the cohort will be with respect to a matched-pair outcome 
analysis of patients who underwent or did not undergo transplantation, we related the age-
corrected morbidity measure in all patients to their current HSCT status. Three patients had 
an early intensive disease course and underwent transplantation within the first 2 years of 
life (Fig 7, A), reflecting the boundary between CID and typical SCID. In contrast, 13 
patients had a mild disease course up to age 12 to 16 years, reflecting the boundary between 
CID and CVID. Although these patients will be informative for analysis of the predictive 
value of immunologic parameters, it is unlikely that they can eventually be matched with 
corresponding (non-) transplanted patients. However, 35 patients (69%) had moderate 
disease severity, where transplant decisions were variable despite similar morbidity. These 
patients provide opportunities for future matched-pair analysis. To visualize the disease 
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course of such matched pairs, we composed a graphical chart reflecting the cumulative 
incidence of CID-related health events over time including a separate display of infections 
and immune dysregulation (Fig 7, B). The charts illustrate that the P-CID study will allow 
comparing patient pairs of similar age and similar disease profile, but divergent HSCT 
decisions. We also used these charts to determine whether grouping patients according to 
their genetic defect would be a better strategy for analysis. Fig E2 in this article’s Online 
Repository at www.jacionline.org illustrates the known clinical heterogeneity in the 7 
RAG1/2 deficient patients, arguing against this approach.
DISCUSSION
The P-CID study targets patients in whom impaired T-cell immunity leads to significant 
complications, but is not severe enough for an unambiguous early transplant decision. For 
these patients, decisions on the indication and time point for HSCT must carefully weigh the 
risks of transplantation against risks of further disease evolution. Given the rarity and 
phenotypic heterogeneity of the individual genetically defined conditions, natural history 
studies are challenging. We hypothesize that a clinical and immunologic rather than a 
genetic definition of P-CID best delineates a cohort in which guidance for transplant 
decisions can be obtained. We therefore initiated a prospective long-term natural history 
study for patients with P-CID. A key feature is the parallel observation of patients with a 
similar clinical course as a result of their T-cell deficiency who undergo or do not undergo 
transplantion in the observation period including a careful analysis of the HSCT decision. 
This interim analysis documents the feasibility of this study approach.
Recently, profound T-cell deficiencies have been defined from different perspectives and it is 
important to relate the P-CID cohort to these definitions (see Table E1 in this article’s 
Online Repository at www.jacionline.org).3,8,14,16,19 From the “perspective of 
HSCToutcome,” the Primary Immune Deficiency Treatment Consortium study 6901 defines 
“leaky” SCID in patients with reduced, but present (>300/μL) T cells (<1000/μL if <2 years, 
<800/μL if 2–4 years, and <600/μL if >4 years) and reduced PHA response or a pathologic 
mutation in a known SCID gene.20 Similarly, “CID” has been delineated from “typical 
SCID” in a retrospective cohort of transplanted patients by more than 500/μL T cells.3 From 
the “diagnostic perspective” of T-cell receptor excision circle–based newborn screening 
(NBS), Kwan et al19 define “leaky” SCID in an infant identified by NBS with 300 to 1500/
μL T cells, reduced naive T cells, and reduced proliferation, supported by an incomplete 
defect in a known SCID gene. Thirteen of the first 50 Primary Immune Deficiency 
Treatment Consortium 6901 patients and 10 of 52 patients identified by NBS fulfilled these 
definitions, all underwent transplantation early, and all 18 with a genetic diagnosis had 
mutations in known SCID genes.19,20 None of these patients would have qualified for our 
study. The NBS study also defines idiopathic T-cell lymphopenia (or variant SCID) as a 
condition with less than 1500/μL, less than 2500/μL, or less than 3505/μL T cells plus “lack 
of naive T cells” defined according to local screening authorities. Fourteen such patients 
have been reported by Kwan et al, all without a molecular diagnosis. Some of these patients 
would probably qualify for the P-CID study once they acquire clinical symptoms during 
follow-up. Thus, the P-CID study targets a unique cohort with minimal overlap to other 
ongoing protocols.
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The P-CID definition was derived from an “intention-to-treat perspective.” We excluded 
patients with T-cell deficiency in whom the treatment decision was clear in infancy. These 
include patients with typical SCID and also patients with normal T-cell numbers, but severe 
functional defects leading to manifestations severe enough for HSCT in infancy (eg, ORAI1, 
IKBK, caspase recruitment domain family, member 11 deficiency, and some patients with 
IL2RGR222C mutations21–23). Instead, we focus on patients in whom the treatment decision 
is less clear. This includes some patients with atypical SCID (as defined in the Introduction) 
that could potentially be identified by NBS, but importantly an equal number of patients 
with forms of bona fide CID (as defined in the Introduction) that will most likely not be 
identified by NBS (eg, ZAP70 deficiency24). Patients with these moderate T-cell deficiencies 
are not specifically recruited by other current studies.
This interim analysis demonstrates that our study protocol indeed recruits the targeted 
patient population. The T-cell inclusion criteria were initially derived from a retrospective 
study on patients with atypical SCID,14 but in this study proved suitable to equally identify 
patients with bona fide CID. A third of the patients had significant lymphopenia, more than 
50% had less than 10% naive T cells, and 61% had reduced/absent PHA proliferation. 
Detailed further phenotypic and functional immunotyping is ongoing. Overall, patients with 
P-CID had the targeted profound T-cell deficiency, which was also reflected by treating 
physician’s decision to use cotrimoxazole prophylaxis and immunoglobulins in 94% and 
78%. Our inclusion criteria in addition required at least 1 severe clinical event. Immune 
dysregulation was frequent as first, predominant, and even only overt manifestation of CID. 
This led to the use of steroids and immunosuppressive drugs in more than half of the 
patients. Overall morbidity was significant with a median of 1 severe event per year, reduced 
QOL, and significant mortality. In accordance with the initial study assumptions, one-third 
of patients underwent transplantation within the first year after study inclusion. Genetic 
diagnoses were equally diverse among patients with atypical SCID and bona fide CID. For 
patients without molecular diagnosis, ongoing genetic studies promise novel insights into the 
molecular regulation of human T-cell immunity. In summary, the P-CID study succeeded in 
recruiting patients with impaired T-cell deficiency associated with significant morbidity, but 
with a spectrum of molecular diagnoses and age profile (median, 9.6 years) that is unique 
and differs from other prospective studies on T-cell deficiencies.
A key question to the study concept is whether the heterogeneity in genetics, disease course, 
and age can be sufficiently controlled to perform comparative outcome analysis with and 
without HSCT or to determine predictors for outcome at the cohort level. First, the 
molecular heterogeneity will have consequences for the immunologic and clinical variability 
of the patients. Some genetic defects will affect T-cell numbers more than T-cell function 
and some defects will in addition affect other immune cell functions. Subgrouping will help 
to determine which of these factors contribute to outcome. Patients in whom additional 
defects outside of the immune system (eg, radiosensitivity) have a significant impact on life 
expectancy or QOL are rare in our cohort and can be excluded for certain elements of the 
analysis. Second, the problem of a variable time of exposure to the risks of the T-cell 
deficiency can be statistically addressed to account for the delayed entry (see this article’s 
Methods section in the Online Repository at www.jacionline.org). Third, we expect that 
different center policies and experience in addition to patient-specific variables including 
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donor availability and the will of the patient’s family will have an impact on the transplant 
decision. Data from this interim analysis illustrate that this variability actually benefits the 
study concept. The P-CID study recruits patients who undergo transplantation soon after 
inclusion and others with similar age and with similar disease severity who do not. We 
expect that among the additional 70 patients, at least 50 will be in the window of interest that 
will allow forming matched pairs for comparative outcome analysis. This is based on the 
fact that we recruit only few patients who are very sick very early (“SCID-like”) and few 
patients who are quite healthy as teenagers (“CVID-like”).
The study results so far confirmed our assumption that the genetic diagnosis has limited 
value as a predictor of disease evolution. There was no relevant difference in age at 
diagnosis, age at first illness, overall age-corrected morbidity, or QOL between patients with 
atypical SCID, bona fide CID, or genetically undefined disease. The highly variable course 
of the 8 patients with RAG deficiency, only 3 of whom have undergone transplantation so 
far, illustrates that knowledge about the affected gene does not imply a clear prognosis and 
treatment decision.
More unexpectedly, our results also indicate that basic measurements of T-cell immunity (ie, 
T-cell numbers, naive T cells, and PHA proliferation) cannot easily identify patients with P-
CID with a poor prognosis. Additional patients in long-term follow-up will help extend these 
initial observations.
In summary, the P-CID study for the first time defines and characterizes a group of patients 
with non-SCID T-cell deficiencies from a therapeutic perspective. This first analysis 
indicates that the P-CID study will reach its study goals. Further recruitment is needed to 
reach 120 patients and study discipline during long-term follow-up will continue to be a 
collaborative challenge. However, the potential of P-CID, both as a clinical study and as a 
unique platform for molecular and immunologic studies by all participants, makes us 
confident that we will achieve our goals.
METHODS
Study protocol
Advanced genetic and immunologic studies.—All patients undergo genetic studies 
according to center policy. If no genetic diagnosis is reached, study consent foresees the 
possibility to perform advanced genetic studies including whole-exome and whole-genome 
sequencing. This is performed in separate research projects outside the clinical study 
protocol. Among members of the P-CID consortium, flow cytometry panels for extensive B- 
and T-cell phenotyping have been standardized. These panels are performed at each study 
visit in all centers offering these investigations. Study consent foresees the possibility of 
using frozen samples for additional phenotypic and functional studies in the context of 
separate research projects. Biomaterial (serum, PBMC, DNA, fibroblasts) is stored locally 
from all patients, and this is documented in the common database at each study visit.
Decision to transplant.—The decision to transplant is an individual decision based on 
the severity of clinical manifestations, the severity of the T-cell deficiency, the local center’s 
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policy (ie, how these factors are interpreted), donor availability, and the will of the patient’s 
family. Reasons for transplanting/not transplanting are carefully documented at every visit. 
The study protocol does not issue recommendations for transplantation indication, donor 
selection, or conditioning regimes.
Outcome parameters.—We analyze overall and event-free survival, the incidence of 
severe events (infections, autoimmunity, malignancy), and the incidence of chronic lung 
disease and QOL at study entry and 5 years after study inclusion. Chronic lung disease is 
defined as the presence of bronchiectasis, interstitial lung disease, or other defined chronic 
lung disease (eg, granulomatous and lymphocytic interstitial lung disease). The severity is 
judged by the impairment of lung function as assessed by lung function testing and by the 
need for home oxygen. A “morbidity measure” is assessed for each patient at study entry 
and 5 years after study inclusion by dividing the cumulative number of clinical events 
(bacterial infections, viral or opportunistic infections, immune dysregulatory events, and 
chronic lung disease) by the patient’s age. QOL is evaluated using the PedsQL Generic Core 
Scales compared with a reference population.E1 Outcome parameters will be compared 
between patients receiving HSCT (group 1) and patients not receiving HSCT (group 2). To 
account for patient heterogeneity, we will also analyze patient outcome in a matched-pair 
analysis. Here, patient pairs with similar age and morbidity measure at study entry, but 
divergent decision on HSCT during follow-up, will be compared. Finally, we will determine 
to which extent clinical events and immunologic parameters and their changes are predictive 
for outcome (survival, morbidity, and QOL). For this, immunologic and clinical data are 
documented retrospectively at study entry and prospectively yearly thereafter.
Statistical considerations
Statistical adjustment for time of exposure.—In the P-CID study, the age at study 
inclusion is between 1 and 16 years and therefore the time of exposure to the risks of the T-
cell deficiency before the controlled observation is variable. Left-truncationE2 is a statistical 
adjustment to account for this fact. It is used when individuals are not observed at the event 
(eg, chronic lung disease) under study but come under observation at some known later time 
(called the left-truncation time). In this case, the calculation of the risk of developing chronic 
lung disease does not include individuals whose left-truncation times exceed the given event 
time (ie, who already have chronic lung disease before study entry).
Predictive value of clinical and immunologic parameters.—We aim to model 
which variables predict whether disease course is mild versus severe using the following 
variables of interest: illnesses (infections, immune dysregulation, malignancy, chronic lung 
disease), CD4 and CD8 T-cell counts, percentage naive T cells, and PHA and anti-CD3 
response. As a statistical model for severe/mild status of patients, we use a multivariable 
logistic regression model with an added least absolute shrinkage and selection operator 
penalty term that simultaneously performs modeling and variable selection for an optimal 
value of a parameter lambda.E3 To determine an optimal value of λ, 17-fold cross-validation 
is used.
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Matched-pair analysis.—The primary variable for matching will be disease severity 
assessed by the morbidity measure at study inclusion. As a secondary variable, patients can 
be selected for age at study entry. Matching for disease category, that is, “atypical” SCID 
versus “bona fide” CID, will be performed only if further observations indicate significant 
clinical differences between these groups (not observed in the “first fifty” analysis). We 
assume that among 120 patients, at least 30 patient pairs can be formed. The pairs will be 
analyzed both visually and analytically. Visually, an assessment will be made by the 
investigators through comparing the plots of the course of clinical events within pairs (see 
Fig 7). For an analytical assessment, binary outcomes such as 5-year survival rates can be 
estimated using conditional logistic regression.
Sample size considerations.—The original study protocol specifies that we intended to 
recruit 120 patients by March 2015 and 200 patients by March 2017, when we wanted to 
close recruitment. Of these, it was estimated that 40% will receive primary HSCT, 30% 
secondary HSCT, and 30% no HSCT. To determine, how many patients would be needed to 
compare outcomes in those undergoing 1 versus 2 versus no HSCT, sample size calculations 
have been performed. Assuming a reference 5-year mortality of 20%, 60 patients in each of 
the 3 groups would allow detecting a relative risk of 2.2 with a power of 80%.
We have currently (February 2016) enrolled 93 patients and have recently initiated a number 
of additional centers including large centers in the United States and Canada. We are 
therefore confident that we can enroll at least 120 patients until March 2017. The initial 
assumptions with respect to HSCT were reasonable, with the reference mortality being 
lower than expected in the range of 10%. The basis for choosing 120 as a revised minimum 
recruitment goal was (1) a pragmatic consideration of the recruitment potential in the Inborn 
Error Working Party/ESID community, (2) a modification of the analysis concept from 3 
groups to 2 groups with group 1 receiving HSCT within the 5-year follow-up and group 2 
remaining without HSCT, and (3) to be able to analyze at least 30 patient pairs 
(transplanted/not transplanted) matched for age and disease severity.
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CID Combined immunodeficiency
CVID Common variable immunodeficiency
HSCT Hematopoietic stem cell transplantation
IL2Rg IL-2 receptor gamma chain
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ITK IL2-inducible T-cell kinase
NBS Newborn screening
ORAI1 ORAI calcium release-activated calcium modulator 1
P-CID Profound combined immunodeficiency
QOL Quality of life
RAG Recombination-activating gene
SCID Severe combined immunodeficiency
ZAP70 Zeta-chain (TCR)-associated protein kinase 70kDa
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Key messages
• P-CID defines a distinct patient group in which impaired T-cell immunity 
leads to significant complications, but is not severe enough for an 
unambiguous transplant decision.
• In the first 51 patients of the P-CID study, neither the genetic diagnosis nor 
basic current measurements of T-cell immunity were good predictors of 
disease evolution.
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FIG 1. 
Overview of the study design and inclusion criteria. A, Each patient is seen in at least 6 
study visits (1 baseline visit and 5 follow-up visits). At each visit, clinical data, laboratory 
data, QOL, and the local center’s decision on HSCT are documented. This decision is not 
influenced by the study protocol. Patients who undergo HSCT within 12 months after 
inclusion are followed in the “early HSCT” arm, the other patients in the “No HSCT” arm. 
Some patients receive HSCT during follow-up (“late HSCT”). After an observation period 
of at least 5 years, survival, QOL, and the frequency of severe clinical events are assessed in 
the whole cohort. B, Inclusion criteria. Nontransplanted HIV-negative patients, 1 to 16 years 
of age, with impaired T-cell immunity and at least 1 severe clinical event are included into 
the study.
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FIG 2. 
Molecular diagnoses and age at study inclusion. A, Among 51 patients, 13 had mutations in 
genes that can also cause a SCID phenotype (“atypical” SCID; left pie chart). Fourteen 
patients had mutations in other genes associated with CID (right pie chart). Twenty-four 
patients currently remain without genetic diagnosis. ADA, Adenosine deaminase; CASP10, 
caspase-10; CORO1A, coronin-1A; DCLRE1C, DNA cross-link repair 1C; DOCK8, 
dedicator of cytokinesis 8; JAK3, Janus kinase 3; LIGIV, ligase IV; NBN, nibrin; PI3KCD, 
phosphoinositide 3-kinase; PNP, purine nucleoside phosphorylase; RAG1/2, recombination-
activating genes 1 and 2; RMRP, RNA component of mitochondrial RNA processing 
endoribonuclease; TPP2, tripeptidyl-peptidase II. B, Age at diagnosis, that is, the time point 
at which the treating physician diagnosed an underlying immunodeficiency. C, Age at 
inclusion into the P-CID study. Data for B and C were evaluated separately for patients with 
atypical SCID, CID, or unknown molecular cause.
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FIG 3. 
Key clinical characteristics of the P-CID study cohort. A, Cumulative percentage of patients 
having suffered from their first immunodeficiency-related illness at a given age for all 
patients (black line) and the 3 subgroups (color code indicated in figure). B, Type of 
immunodeficiency-related illnesses within the first year of clinical presentation. 1, invasive 
bacterial infection; 2, severe acute viral infection; 3, persistent viral infection; 4, 
opportunistic infection; 5, other infection; 6, autoimmune disease; 7, skin disease; 8, 
gastrointestinal disease; 9, lymphoproliferation; 10, autoimmune cytopenia; 11, chronic lung 
disease; 12, other ID-related organ complication. C, Overall frequency of severe clinical 
events. The pie chart illustrates the relative frequency of all individual clinical events 
observed in all patients of the cohort. The number indicates the mean number of events per 
year among all patients in the study. D, Relative distribution of infections versus 
manifestations of immune dysregulation as defined for the morbidity measure for all 
individual patients (mild disease course, open triangles; severe disease course, filled 
triangles). “50%” indicates an equally balanced distribution of infections/immune 
dysregulation events. Patients between the range of 50% to 100% predominantly had 
manifestations of immune dysregulation, and patients between the range of 0% to 50% 
predominantly had infections. Gray bars summarize the individual patients in groups.
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FIG 4. 
Morbidity assessment and baseline QOL of the P-CID study cohort. A, Morbidity measure 
in patients with atypical SCID, CID, and unknown molecular diagnosis. B, QOL at study 
entry as assessed by PedsQL Generic Core Scales of patients with atypical SCID, CID, and 
unknown molecular diagnosis vs a reference population of healthy children.E1
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FIG 5. 
Immunologic parameters at study inclusion. In A-C, data are shown separately for patients 
with atypical SCID, CID, and unknown molecular diagnosis. Filled triangles represent 
patients with a severe disease course, open triangles patients with a mild disease course. A, 
Counts of CD4 T cells (left panel) and CD8 T cells (right panel). B, Naive CD4 T cells 
determined as percentage of CD45RA+CD62L+ or CD45RA+CD31+ of CD4 T cells. C, 
Percentage of γ/δ TCR+ among CD3 T cells. D, T-cell proliferation response (absent, <10%; 
low, 10% to 30%; normal, >30% of local control) after stimulation with PHA.
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FIG 6. 
Patients undergoing HSCT since study inclusion. Kaplan-Meyer curve indicating the 
cumulative percentage of patients who underwent transplantation at a given time after study 
inclusion. Results are shown for all patients (black line) and the 3 subgroups (color code 
indicated in figure). Vertical lines indicate the time point of censoring for individual patients. 
The absolute number of patients at risk at a given time is indicated at the top of the figure.
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FIG 7. 
Graphical illustration documenting the feasibility of the planned matched-pair analysis. A, 
Assessment of morbidity measures plotted against the age at study inclusion for all patients. 
Patients who underwent transplantation within the first year after inclusion are represented 
by filled triangles, nontransplanted patients by open triangles. Inside the black-rimmed box 
are patients who will be included in the future matched-pair analysis. Outside the box are 
patients who are either very sick very early (“SCID-like,” left outside the box) or patients 
who are quite healthy as teenagers (“CVID-like,” right outside the box) and therefore not 
informative for the matched-pair analysis. The circle indicates the patient pair further 
visualized in B. B, Example of a patient pair with a similar morbidity measure who will 
quality for a matched-pair analysis. The staircase diagrams summarize the clinical course of 
an individual patient over time. Individual clinical events are indicated by an upward step on 
the y-axis. The cumulative course of all clinical events per patient is indicated by a black 
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line. A separate analysis of infections and manifestations of immune dysregulation is given 
in red and blue, respectively.
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FIG E1. 
Correlation of different parameters assessing disease severity. A, Mean cumulative number 
of events at a given age for patients judged to have a severe (dashed line) or a mild disease 
course (solid line) at study entry. The absolute number of patients at risk at a given time is 
indicated in the line above the figure. B, QOL scores at study entry for patients with a severe 
or a mild disease score. C, Morbidity measure in patients with severe and mild disease 
course as judged by the treating physician.
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FIG E2. 
Summary of clinical course of RAG-deficient patients. Each staircase diagram summarizes 
the clinical course of an individual patient with a mutation in RAG1 or 2 over time. 
Individual clinical events are indicated by an upward step on the y-axis. The cumulative 
course of all clinical events per patient is indicated by a black line. A separate cumulative 
analysis of infections and manifestations of immune dysregulation is given in red and blue, 
respectively. Black circles in the upper left corner indicate patients who underwent HSCT 
less than 1 year after study inclusion. Red circles in the upper right corner indicate patients 
with severe course as judged by their primary physician.
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TABLE E1.
Current definitions of non-SCID T-cell disorders
Condition Clinical criteria T-cell criteria Genetic criteria Source
“Leaky” SCID Treatment with HSCT CD3 <1000/μL (<2 y), <800/μL (2–4 y), 
<600/μL (>4 y)
AND PHA < 30% of lower limit
AND absence of maternal engraftment
None Shearer et alE4
“Leaky” SCID Infant identified by NBS 
because of low TRECs
CD3 300–1500/μL
AND naive T cells reduced
AND T-cell proliferation reduced
Incomplete defect 
in known SCID 
gene
Kwan et alE5
“Variant” SCID Infant identified by NBS 
because of low TRECs
<1500/μL, <2500/μL, or <3505/μL T cells None Kwan et alE5
“Atypical” SCID Not transplanted in first year of 
life
CD31 T-cell counts above 100/μL at 
diagnosis
Mutation in 
known SCID gene
Felgentreff et alE6
P-CID Not transplanted in first year of 
life
AND at least 1 of the following:
 Major infection
 Major immune dysregulation
 Malignancy
At least 2 of the following:
 CD4: <700, if <2 y; <500, if 2–4 y; <300, 
if >4 y;
 OR CD8: <350, if <2 y; <250, if 2–4 y; 
<150, if >4 y
 OR naive CD41: <30% <2 y, <25% 2–6 
y, <20% >6y
 OR PHA or anti-CD3 <30% of lower 
limit
 OR g/δ T cells >15% of total CD3
None This study
CID Treatment with HSCT CD3 >500/mL None Roifman et alE7
CVID Age >4 y AND at least 1 of the 
following
 Increased susceptibility to 
infection
 Autoimmune manifestations
 Granulomatous disease
 Unexplained polyclonal 
lymphoproliferation
 Affected family member with 
antibody deficiency
At least 1 of the following:
 Marked decrease in IgG AND marked 
decrease in IgA
 Poor antibody response to vaccines OR 
absent isohemagglutinins AND no evidence 
of profound T-cell deficiency (2 of the 
following)
 CD4: 4–6 y <300/μL, 6–12 y <250/μL, 
>12 y <200/μL
 OR naive CD4: 4–6 y <25%, 6–16 y 
<20%, >16 y <10%
 OR T-cell proliferation absent
None ESID Registry
TREC, T-cell receptor excision circle.
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